HCW9206試劑也已提交美國食品藥品監督管理局。

該公司現在正在尋求HCW9206試劑銷售和/或集成到基於CAR-T的製造過程中的商業合作夥伴關係。

HCW Biologics (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on cellular immunotherapy for hematological malignancies, chronic infections and autoimmune diseases, today announced the publication of new preclinical data in the Journal of Immunological Methods demonstrating the potential of HCW9206, the Company’s proprietary ex vivo T cell reagent, to improve the long-term survival of adoptive transfer cells and facilitate durable suppression of malignancies, chronic infections and autoimmune diseases.

HCW生物製劑（NASDAQ：HCWB）是一家臨床階段的生物製藥公司，重點是細胞免疫療法，用於血液學惡性腫瘤，慢性感染和自身免疫性疾病，今天宣佈在《免疫方法》中發表了新的抗性方法，以改善了HCW9206206206206206的潛在，該雜誌在收養轉移細胞的存活，並促進對惡性腫瘤，慢性感染和自身免疫性疾病的持久抑制。

“We are excited to share these preclinical data demonstrating the potential of HCW9206 to enhance the persistence and anti-tumor activity of CAR-T cells in relevant disease models,” said Peter Rhode, Chief Scientific Officer and Vice President Clinical Operations at HCW Biologics. “These findings provide further support for the development of HCW9206 as a valuable addition to CAR-T manufacturing processes.”

“我們很高興共享這些臨床前數據，證明了HCW9206在相關疾病模型中增強CAR-T細胞的持久性和抗腫瘤活性的潛力。” “這些發現為HCW9206的開發提供了進一步的支持，這是對CAR-T製造過程的寶貴補充。”

In a preclinical model of triple-negative breast cancer, CAR-T cells displayed poor persistence and limited anti-tumor activity. However, the introduction of HCW9206 led to a significant improvement in CAR-T cell persistence, resulting in complete tumor regression and long-term survival. Moreover, the combination of CAR-T cells with HCW9206 effectively suppressed tumor growth and led to the survival of all treated animals, while untreated animals succumbed to cancer progression.

在三陰性乳腺癌的臨床前模型中，CAR-T細胞的持久性較差和抗腫瘤活性有限。但是，HCW9206的引入導致CAR-T細胞持久性的顯著改善，從而導致腫瘤的完全消退和長期生存。此外，CAR-T細胞與HCW9206的組合有效地抑制了腫瘤的生長，並導致了所有治療的動物的存活，而未經治療的動物則屈服於癌症的進展。

Furthermore, in a preclinical model of HIV infection, CAR-T cells treated with HCW9206 exhibited superior persistence and viral suppression compared to untreated CAR-T cells. This finding suggests that HCW9206 could be instrumental in enhancing the efficacy of adoptive T cell transfer for the treatment of chronic infections.

此外，與未經治療的CAR-T細胞相比，用HCW9206處理的HCW9206治療的CAR-T細胞表現出優越的持久性和病毒抑制。這一發現表明，HCW9206可能有助於增強收養T細胞轉移治療慢性感染的功效。

Finally, in a preclinical model of rheumatoid arthritis, CAR-T cells treated with HCW9206 displayed reduced differentiation into memory stem cells and a lower expression of pro-inflammatory cytokines, indicating a potential reduction in the incidence and severity of autoimmune reactions.

最後，在類風濕關節炎的臨床前模型中，用HCW9206處理的CAR-T細胞顯示出分化減少到記憶幹細胞中，促炎細胞因子的表達較低，表明自動免疫反應的發生率和嚴重程度可能降低。

The ex vivo reagent has also been filed with the US Food and Drug Administration. The Company is now seeking commercial partnerships for HCW9206 reagent sale and/or integration into CAR-T based manufacturing processes.

體內試劑也已提交給美國食品和藥物管理局。該公司現在正在尋求HCW9206試劑銷售和/或集成到基於CAR-T的製造過程中的商業合作夥伴關係。

About HCW Biologics

關於HCW生物製劑

HCW Biologics (Nasdaq: HCWB) is a clinical-stage biopharmaceutical company developing cellular immunotherapies for hematological malignancies, chronic infections and autoimmune diseases. The Company’s mission is to create best-in-class immuno-modulating therapies that could transform the lives of patients.

HCW Biologics（NASDAQ：HCWB）是一家臨床階段的生物製藥公司，開髮用於血液惡性腫瘤，慢性感染和自身免疫性疾病的細胞免疫療法。該公司的任務是創建一流的免疫調節療法，以改變患者的生活。

The Company’s programs are based on its proprietary iPSC-derived immune cell platform, which enables the generation of homogenous and scalable cell populations with defined properties. HCW Biologics is currently developing a portfolio of programs targeting triple-negative breast cancer, HIV infection and rheumatoid arthritis.

該公司的計劃基於其專有IPSC衍生的免疫細胞平台，該平台可以生成具有定義性能的同質和可擴展的細胞群體。 HCW Biologics目前正在開發針對三陰性乳腺癌，HIV感染和類風濕關節炎的程序組合。

HCW Biologics is headquartered in Rockville, Maryland.

HCW Biologics總部位於馬里蘭州羅克維爾。

Company Contact:

公司聯繫人：

Chief Scientific Officer and Vice President Clinical Operations

首席科學官兼副總裁臨床行動

HCW Biologics Inc.

peterrhode@hcwbiologics.com